378 related articles for article (PubMed ID: 26295307)
1. The 26S proteasome is a multifaceted target for anti-cancer therapies.
Grigoreva TA; Tribulovich VG; Garabadzhiu AV; Melino G; Barlev NA
Oncotarget; 2015 Sep; 6(28):24733-49. PubMed ID: 26295307
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
3. [Ubiquitin-proteasome pathway as a target for therapeutic strategies].
Staszczak M
Postepy Biochem; 2017; 63(4):287-303. PubMed ID: 29374430
[TBL] [Abstract][Full Text] [Related]
4. NEDD4: a promising target for cancer therapy.
Ye X; Wang L; Shang B; Wang Z; Wei W
Curr Cancer Drug Targets; 2014; 14(6):549-56. PubMed ID: 25088038
[TBL] [Abstract][Full Text] [Related]
5. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
[TBL] [Abstract][Full Text] [Related]
6. The significance of ubiquitin proteasome pathway in cancer development.
Yerlikaya A; Yöntem M
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy.
Aliabadi F; Sohrabi B; Mostafavi E; Pazoki-Toroudi H; Webster TJ
Open Biol; 2021 Apr; 11(4):200390. PubMed ID: 33906413
[TBL] [Abstract][Full Text] [Related]
8. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
10. Effect of Ferulic Acid, a Phenolic Inducer of Fungal Laccase, on 26S Proteasome Activities In Vitro.
Swatek A; Staszczak M
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32252291
[TBL] [Abstract][Full Text] [Related]
11. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
12. [Ubiquitin-independent protein degradation in proteasomes].
Buneeva OA; Medvedev AE
Biomed Khim; 2018 Mar; 64(2):134-148. PubMed ID: 29723144
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in proteasome inhibitor-based cancer therapies.
Dou QP
Curr Cancer Drug Targets; 2014; 14(6):505. PubMed ID: 25092106
[No Abstract] [Full Text] [Related]
14. Pharmacophore modeling technique applied for the discovery of proteasome inhibitors.
Pautasso C; Troia R; Genuardi M; Palumbo A
Expert Opin Drug Discov; 2014 Aug; 9(8):931-43. PubMed ID: 24877566
[TBL] [Abstract][Full Text] [Related]
15. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Landré V; Rotblat B; Melino S; Bernassola F; Melino G
Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
[TBL] [Abstract][Full Text] [Related]
16. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes.
Grover A; Shandilya A; Bisaria VS; Sundar D
BMC Genomics; 2010 Dec; 11 Suppl 4(Suppl 4):S15. PubMed ID: 21143798
[TBL] [Abstract][Full Text] [Related]
17. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
[TBL] [Abstract][Full Text] [Related]
18. The immunoproteasome as a therapeutic target for hematological malignancies.
Miller Z; Lee W; Kim KB
Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
[TBL] [Abstract][Full Text] [Related]
19. 26S proteasomes become stably activated upon heat shock when ubiquitination and protein degradation increase.
Lee D; Goldberg AL
Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2122482119. PubMed ID: 35704754
[TBL] [Abstract][Full Text] [Related]
20. Measurement of the Multiple Activities of 26S Proteasomes.
Kim HT; Collins GA; Goldberg AL
Methods Mol Biol; 2018; 1844():289-308. PubMed ID: 30242717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
